Online citations, reference lists, and bibliographies.
← Back to Search

Initial Bone Marrow Aspiration In Childhood Idiopathic Thrombocytopenia: Decision Analysis

R. Klaassen, J. Doyle, M. Krahn, V. Blanchette, G. Naglie
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Purpose Bone marrow aspiration (BMA) is routinely performed before starting steroid therapy in children with idiopathic thrombocytopenia, primarily to rule out leukemia. Methods A decision tree for the initial management of a child older than age 6 months, presenting with idiopathic thrombocytopenia, without blasts on the peripheral smear was constructed. The three strategies are: 1) initial BMA in all patients; 2) initial BMA only in patients at high risk; and 3) empiric therapy for all patients without initial BMA. High-risk criteria include any of: platelet count >50 × 10 9 /L; hemoglobin <100g/L (age younger than 12 months) or <110g/L (age older than 12 months); white blood cell count <5 × 10 9 /L (younger than 6 years) or <4 × 10 9 /L (older than 6 years); or absolute neutrophil count <1.5 × 10 9 /L (younger than 6 years) or <2 × 10 9 /L (older than 6 years). The results are expressed as quality-adjusted life years (QALYs), a measure that estimates the overall life expectancy in years for patients receiving a particular treatment strategy, corrected for the patient's quality of life. Results The base case results are: 1) BMA all = 69.649 QALYs; 2) high-risk BMA = 69.652 QALYs; and 3) empiric therapy = 69.644 QALYs. These results indicate a three-way toss-up because there is less than a 4-day quality-adjusted difference (0.01) between strategies. Conclusion This study indicates that the initial BMA does not significantly change the overall QALYs of a child presenting with thrombocytopenia and, consequently, is not mandatory in every patient before starting steroids.
This paper references
A prospective epidemiological study
Edm. Tod (1964)
A utility maximization model for evaluation of health care programs.
G. Torrance (1972)
10.1016/0038-0121(76)90036-7
Social preferences for health states: An empirical evaluation of three measurement techniques
G. Torrance (1976)
10.1016/S0140-6736(82)90116-7
IS RENAL BIOPSY NECESSARY IN ADULTS WITH NEPHROTIC SYNDROME?
M. Hlatky (1982)
10.7326/0003-4819-99-2-199
Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival.
D. Ransohoff (1983)
10.1056/NEJM198306023082206
Economic evaluation of neonatal intensive care of very-low-birth-weight infants.
M. Boyle (1983)
10.2307/2683121
PC-SIZE: A Program for Sample-Size Determinations
G. Dallal (1986)
10.1001/ARCHPEDI.1988.02150050046027
Is bone marrow examination justified in idiopathic thrombocytopenic purpura?
D. Halpérin (1988)
10.1016/S0022-3476(88)80163-X
Cost-effectiveness of splenectomy versus intravenous gamma globulin in treatment of chronic immune thrombocytopenic purpura in childhood.
J. Hollenberg (1988)
Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study.
A. Dubansky (1989)
10.1017/S0266462300008461
Utilities and quality-adjusted life years.
G. Torrance (1989)
10.1182/BLOOD.V78.5.1166.BLOODJOURNAL7851166
Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
G. Henze (1991)
10.1111/j.1651-2227.1992.tb12175.x
Bone marrow examination before steroids in thrombocytopenic purpura or arthritis
M. Reid (1992)
10.1136/adc.67.8.1056
Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.
O. Eden (1992)
10.1016/S0022-3476(05)80400-7
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.
V. Blanchette (1993)
10.1016/S0140-6736(94)92205-5
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura
V. Blanchette (1994)
10.1056/NEJM199412153312402
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
K. Bjøro (1994)
10.1136/ADC.71.3.251
Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology.
J. Lilleyman (1994)
10.1001/JAMA.1994.03520100035030
Screening for prostate cancer. A decision analytic view.
M. Krahn (1994)
10.7326/0003-4819-120-6-199403150-00001
Managing Chronic Atrial Fibrillation: A Markov Decision Analysis Comparing Warfarin, Quinidine, and Low-Dose Amiodarone
D. Disch (1994)
10.1023/A:1008487912288
Screening for prostate cancer.
D. Neal (1994)
The meaning of life expectancy: what is a clinically significant gain
D Naimark (1994)
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin (see comments)
K Bjoro (1994)
10.1182/BLOOD.V85.11.3058.BLOODJOURNAL85113058
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.
S. Rosenfeld (1995)
10.1016/S0140-6736(95)90164-7
Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X
J. Chessells (1995)
10.1002/1097-0142(19950401)75:7<1684::AID-CNCR2820750720>3.0.CO;2-2
Good steroid response in vivo predicts a favorable outcome in children with T‐cell acute lymphoblastic leukemia
M. Aricò (1995)
10.1097/00043426-199502000-00001
The Use of Glucocorticoids in Acute Lymphoblastic Leukemia of Childhood Molecular, Cellular, and Clinical Considerations
P. Gaynon (1995)
10.1016/S0360-3016(96)00272-6
Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group.
J. Cherlow (1996)
10.1136/adc.74.4.319
Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome.
N. Clausen (1996)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
10.1097/00005650-199607000-00004
Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2.
G. Torrance (1996)
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the
J N George (1996)
10.7326/0003-4819-126-2-199701150-00003
Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy
K. Doney (1997)
Cardiac arrest during anesthesia in a teaching hospital. A 4 years survey.
K. H. Wu (1997)
10.1182/BLOOD.V90.3.1009.1009_1009_1013
Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.
A. Ohara (1997)
Cardiac arrest during anesthesia in a teaching hospital. A 4 years survey.
Wu Kh (1997)
10.1001/ARCHPEDI.152.4.345
Is Bone Marrow Aspiration Needed in Acute Childhood Idiopathic Thrombocytopenic Purpura to Rule Out Leukemia
C. Calpin (1998)
Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? Arch Pediatr
C Calpin (1998)
Food and Drug Administration, Department of Health and Human Services, Public Health
JS Epstein (1998)
10.1097/00043426-200001000-00011
Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists.
S. Vesely (2000)
10.1200/JCO.2000.18.4.813
Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
B. Pollock (2000)
10.1097/00043426-200007000-00042
Transient acute renal failure (ARF) and anti-D intravascular hemolysis (IVH) following intravenous (IV) treatment of immune thrombocytopenia (ITP)
R. Gera, (2000)
10.1001/ARCHINTE.160.11.1630
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
Yoram Cohen (2000)
10.1097/00000542-200007000-00007
Anesthesia-related Cardiac Arrest in Children: Initial Findings of the Pediatric Perioperative Cardiac Arrest (POCA) Registry
Jeffrey P. Morray (2000)
Food and Drug Administration, Department of Health and Human Services
J S Epstein



This paper is referenced by
10.1182/bloodadvances.2019000812
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
D. Provan (2019)
10.1007/s12288-015-0533-2
Re-evaluation of Need for Bone Marrow Examination in Patients with Isolated Thrombocytopenia Contributors
A. Purohit (2015)
Evaluation of Prognostic Factors in Newly Diagnosed Childhood Primary Immune Thrombocytopenia ( ITP ) : Two-Year Prospective Study at Al-Sadder Hospital , Missan Province
S. Al-Zuhairy (2013)
10.1111/ijlh.12073
Bone marrow evaluation for pediatric patients
M. Proytcheva (2013)
10.5581/1516-8484.20130105
Guidelines on the diagnosis of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012
J. P. Braga (2013)
10.1016/j.pedhc.2012.04.001
Menorrhagia and rash in a female adolescent.
Rachel Berquist (2013)
10.1136/adc.2010.184234
Changing trends in the UK management of childhood ITP
J. Grainger (2011)
10.1177/0272989X11400417
Decision Modeling of Disagreements
H. Lehmann (2011)
10.1182/blood-2009-06-225565
International consensus report on the investigation and management of primary immune thrombocytopenia.
D. Provan (2010)
primary immune thrombocytopenia International consensus report on the investigation and management of
Miguel A. Sanz (2010)
10.26719/2009.15.3.729
Immune thrombocytopenia in children with reference to low-income countries.
A. Rehman (2009)
10.1016/j.pcl.2008.01.004
Decision analysis in pediatric hematology.
S. O'Brien (2008)
Evaluación del paciente con trombocitopenia
G. Maya (2007)
10.1097/MOH.0b013e3282ab98df
Update on the management of immune thrombocytopenic purpura in children
M. Tarantino (2007)
10.1002/pbc.20894
What is the “cost” of acute ITP?
G. Buchanan (2007)
10.1097/MOH.0b013e3282ab98f2
Diagnosis of immune thrombocytopenic purpura in children
A. Geddis (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
10.1080/08035250500486660
Initial management of children with newly diagnosed idiopathic thrombocytopenic purpura in the Nordic countries.
I. Treutiger (2006)
Pauta de tratamiento del púrpura trombocitopénico inmune
M. Caggiani (2006)
10.1007/3-540-29036-2_45
Klinische Tumordiagnose und Differenzialdiagnose
B. Selle (2006)
10.1002/pbc.20968
Current challenges in the management of children with idiopathic thrombocytopenic purpura
G. Buchanan (2006)
10.1111/j.1651-2227.2006.tb02322.x
Initial management of children with newly diagnosed idiopathic thrombocytopenic purpura in the Nordic countries
I. Treutiger (2006)
10.1016/B978-012348776-6/50025-X
Chapter 22 – Platelet Transfusions in the Infant and Child
M. Saxonhouse (2004)
10.1007/s00112-004-0925-0
Immunthrombozytopenische Purpura bei Kindern
H. Gadner (2004)
10.1016/S0210-5705(03)70410-5
Colitis ulcerosa asociada a púrpura trombocitopénica idiopática
A. P. Maestu (2003)
10.1097/00043426-200312001-00014
Using Decision Analysis Techniques to Deal With “Unanswerable” Questions in Idiopathic Thrombocytopenic Purpura
R. Klaassen (2003)
Guest Commentary Assessing the Overall Impact of Therapy: It’s Not So Simple
(2002)
10.1093/PCH/7.6.384
Acute immune thrombocytopenic purpura: What do we do when things go well?
R. Klaassen (2002)
10.1097/00043426-200210000-00008
Randomized Trial of High-Dose Methylprednisolone Versus Intravenous Immunoglobulin for the Treatment of Acute Idiopathic Thrombocytopenic Purpura in Children
K. G. Ancona (2002)
10.1097/00043426-200210000-00004
Assessing the overall impact of therapy: it's not so simple.
P. Breitfeld (2002)
Semantic Scholar Logo Some data provided by SemanticScholar